MicroRNA-221: A Context-Dependent Mediator in Human Diseases—Highlights from Molecular Mechanisms to Clinical Translation
Cells · 2025
DOI: 10.3390/cells14231896 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, 2025. Verfasst von Qiu-Xiao Ren und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathophysiology, Naval Medical University, Shanghai 200433, China. Hauptthemen laut MEDLINE: MicroRNAs, Translational Research, Biomedical. Die Arbeit nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
MicroRNA-221 (miR-221), a conserved small non-coding RNA, acts as a pivotal modulator of biological processes across multiple organ systems, the dysregulation of which is closely linked to the pathogenesis of various human diseases. This review systematically summarizes its multifaceted roles in cancer, cardiovascular diseases (CVDs), neurological disorders, digestive system diseases, respiratory conditions, and adipose-endocrine dysfunction. In cancer, miR-221 exerts context-dependent oncogenic/tumor-suppressive effects by targeting phosphatase and tensin homolog (PTEN), cyclin-dependent kinase inhibitor 1c (CDKN1C/p57), and BCL2 modifying factor (Bmf), thereby regulating cell proliferation, invasion, stemness, and resistance to cancer therapy; it also serves as a non-invasive biomarker for glioma, papillary thyroid carcinoma, and colorectal cancer. In the cardiovascular system, it balances antiviral defense in viral myocarditis, modulates ventricular fibrotic remodeling in heart failure, and regulates endothelial function in atherosclerosis, with cell-type/ventricle-specific effects. In neurological disorders, it protects dopaminergic neurons in Parkinson’s disease and modulates microglial activation in epilepsy. It also regulates hepatic pathogen defense and intestinal mucosal immunity. Mechanistically, miR-221 alters cellular phenotypes by targeting tumor suppressors or signaling components (e.g., PI3K/AKT, TGF-β/suppressor of mothers against decapentaplegic homolog(SMAD), Wnt/β-catenin). Therapeutically, miR-221-targeting strategies show preclinical promise in cancer and CVDs. Despite this progress, further studies are needed to resolve context-dependent functional discrepancies, validate biomarker utility, and develop cell-specific delivery systems. This review provides a framework to understand its pathophysiologcial roles and potential application as a biomarker and therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathophysiology, Naval Medical University, Shanghai 200433, China.
- Experimental Teaching Center, College of Basic Medical Sciences, Naval Medical University, Shanghai 200433, China.
- College of Basic Medical Sciences, Naval Medical University, Shanghai 200433, China.
ORCID-Profile: Qiu-Xiao Ren, An-Jing Ren
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Ren, Q. X., Zhao, Q., Wu, N., Du, W., Liu, Z., Zhang, W. J., & Ren, A. J. (2025). MicroRNA-221: A Context-Dependent Mediator in Human Diseases—Highlights from Molecular Mechanisms to Clinical Translation. Cells. https://doi.org/10.3390/cells14231896
Vancouver
Ren QX, Zhao Q, Wu N, Du W, Liu Z, Zhang WJ, et al. MicroRNA-221: A Context-Dependent Mediator in Human Diseases—Highlights from Molecular Mechanisms to Clinical Translation. Cells. 2025. doi:10.3390/cells14231896
BibTeX
@article{Ren2025,
author = {Ren, Qiu-Xiao and Zhao, Qian and Wu, Na and Du, Wanying and Liu, Zhaoyue and Zhang, Weiping J and Ren, An-Jing},
title = {MicroRNA-221: A Context-Dependent Mediator in Human Diseases—Highlights from Molecular Mechanisms to Clinical Translation},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14231896}
}
EUVIMED